Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Maverick Therapeutics Inc.

Headquarters: Brisbane, CA, United States of America
Website: N/A
Year Founded: 2016
Status: Acquired

BioCentury | May 25, 2022
Management Tracks

Manner becomes CEO of OraSure

Plus Afeyan to chair Rubius, Chroma adds Golumbeski to board, Maraganore as adviser 
BioCentury | Feb 2, 2022
Management Tracks

Roche’s William Pao joins Pfizer as CDO

Plus Clevers succeeds Pao at Roche, new CEO, CFO and other changes at Sosei and updates from Biomea, BeiGene, Cortexyme and more
BioCentury | Jan 10, 2022
Deals

Adaptate takeout is Takeda’s latest move in γδ sector

Build-to-buy deal gives Takeda set of γδ antibodies, paired with existing T cell therapy holdings
BioCentury | Sep 23, 2021
Management Tracks

Alnylam vet Smith joins MPM

Plus: Yi to leave Cerevel, Dicerna, Verastem, MiroBio,
BioCentury | Jun 17, 2021
Management Tracks

Syncona expands C-suite; plus Myriad, Aulos, Cytovia, Elevation and more

Syncona Ltd. (LSE:SYNC) hired Rolf Soderstrom as CFO, Markus John as CMO and head of R&D and Fiona Langton-Smith as chief human resources officer. Soderstrom, who previously served as CFO of BTG
BioCentury | Jun 15, 2021
Management Tracks

Avila joins Atea as SVP of medical affairs; plus Werewolf, Senda, Aurion, Sigilon and more

Viral infections company Atea Pharmaceuticals Inc. (NASDAQ:AVIR) hired Claudio Avila as SVP of medical affairs. Avila joins from Gilead Sciences Inc. (NASDAQ:GILD), where he was executive director of
BioCentury | Mar 16, 2021
Deals

Vaccine vexed; plus assessing Lilly’s Alzheimer’s data & PDUFA preview: a BioCentury podcast

The only thing that’s clear from the latest big Alzheimer’s readout is that the entrenched camps of amyloid believers and doubters will take predictably polarized views. On the latest
BioCentury | Mar 10, 2021
Deals

Maverick takeout adds T cell-engagers to Takeda’s solid tumor toolkit

The acquisition fits squarely in Takeda’s transformation from a small molecule company to one built on multiple modalities. 
BioCentury | Aug 8, 2019
Emerging Company Profile

Akrevia: Masking immunotherapies en route to tumors

Akrevia is getting around immunotherapy toxicity by masking biologics until they reach tumor microenvironment
Items per page:
1 - 10 of 26
Help Center
Username
Request a Demo
Request Training
Ask a Question